

Report to:



Item: 8.2

Date of Meeting:	25 May 2018		
Title of Report:	Research and Development Annual Report 2017-18		
Presented by: Author:	Sarah Smyth, Director of Quality & Clinical Governance / Executive Nurse Danielle Hook , R and D Manager Dr M Girdham R and D Lead Manager (Humber)		
STATUS OF THE R	PEPORT.		
To appro To ratify To consid To note	ve To endorse To discuss		
PURPOSE OF REPORT: The purpose is to present the R and D Annual report 2017 -18 to the CCG Board. The report provides the full year (2017-18) activity and end of study information that has been undertaken.  RECOMMENDATIONS:  a That the CCG Board note the R and D Annual Report 2017 - 18			
REPORT EXEMPT FROM PUBLIC DISCLOSURE  No X Yes  If yes, detail grounds for exemption			
CCG STRATEGIC OBJECTIVE (See guidance notes on page 4)  1, 7, 8 and 12  Short summary as to how the report links to the CCG's strategic objectives  The R and D Annual Report inform the CCG of how it is working to meet the statutory duty to promote research and the use of research evidence in commissioning towards achieving its strategic objectives.			

NHS Hull Clinical Commissioning Group Board

IMPLICATIONS: (summary of key implications, including risks, associated with the paper),		
Finance	The R and D agenda have implications for NHS Hull CCG financial planning and reporting of funds used towards supporting research and development (R and D)	
HR	None	
Quality	Support for involving the patients in research studies is one of the indicators for quality health care and a mandatory part of the quality reports accounts.	
Safety	All patients in research are required to be treated in accordance with safety mechanisms described in the Good Clinical practice requirements. Also referred to in the Department of Health; Research Governance Framework and the UK legal acts.	

**ENGAGEMENT:** (Explain what engagement has taken place e.g. Partners, patients and the public prior to presenting the paper and the outcome of this)

All National Institute of Health Research (NIHR) portfolio-adopted research studies that include excess treatment costs require to be compliant with DOH and National Health Service (NHS) policies on having patient input provided in relation to the design and rationale for research studies, including an opportunity to be fully informed about the study procedures. All research projects supported by NHS Hull CCG require demonstrating patient involvement in the project design, rationale and /or participation including provision of full information and formal consent procedures consistent with DOH Research Governance Framework (RGF).

**LEGAL ISSUES:** (Summarise key legal issues / legislation relevant to the report)

NHS Hull CCG is legally required to support research, principally through the funding of excess treatment cost for patients taking part in research (Health and Social Care Act, 2012).

**EQUALITY AND DIVERSITY ISSUES:** (summary of impact, if any, of CCG's duty to promote equality and diversity based on Equality Impact Analysis (EIA). **All** reports relating to new services, changes to existing services or CCG strategies / policies **must** have a valid EIA and will not be received by the Committee if this is not appended to the report)

	Tick relevant box
An Equality Impact Analysis/Assessment is not required for this report.	Х
An Equality Impact Analysis/Assessment has been completed and approved by the lead Director for Equality and Diversity. As a result of performing the analysis/assessment there are no actions arising from the analysis/assessment.	
An Equality Impact Analysis/Assessment has been completed and there are actions arising from the analysis/assessment and these are included in section xx in the enclosed report.	

THE NHS CONSTITUTION: (How the report supports the NHS Constitution)

The NHS Constitution confirms the commitment of the NHS 'to the promotion and conduct of research.' NHS Hull CCG is fully compliant with this provision of the NHS Constitution.